Accelerating innovation in viral vector processing
Develop, optimise and scale-up your viral vector project with our Biotherapeutics capabilities
![Pharmaceutical label production Pharmaceutical label production](https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-lead-image.jpg?w=1920&h=1080&q=60&fm=jpg&fit=crop&dm=1559218256&s=b39f42ffc18c0242f02b74c10f00c5ce 1920w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-lead-image.jpg?w=1120&h=630&q=60&fm=jpg&fit=crop&dm=1559218256&s=394d7bb4536f708cd1999d26d89b72f8 1120w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-lead-image.jpg?w=800&h=450&q=60&fm=jpg&fit=crop&dm=1559218256&s=f02ff159c5aa5a650c483a90ef82c837 800w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-lead-image.jpg?w=1600&h=900&q=45&fm=jpg&fit=crop&dm=1559218256&s=dfca03f65e0bb5e166a5d21072acb687 1600w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-lead-image.jpg?w=480&h=270&q=60&fm=jpg&fit=crop&dm=1559218256&s=87c0d1c7b89ba87903f794252a2c0afa 480w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-lead-image.jpg?w=960&h=540&q=45&fm=jpg&fit=crop&dm=1559218256&s=1ff77c14b3b2f37630a1eaeda71ab656 960w)
We are a leading independent technology innovation centre and a founding member of the UK Government’s High Value Manufacturing Catapult. Established in 2004, our teams tirelessly apply their many years of experience to ensure that every great invention gets the best opportunity to become a successfully marketed product or process.
We help companies to develop, prove, and scale-up the next generation of biologic products and processes and provide our partners with access to the following capabilities:
-
Access to bioprocess development and scale-up experts.
-
End-to-end workflow, from small scale to large scale manufacturing.
-
Experience with a range of AAV serotypes and lentiviral vectors.
-
Access to a diverse range of equipment and expertise.
-
Tech transfer to a client’s manufacturing facility or CMO.
-
Expertise in formulation, cryopreservation development, forced degradation and stability studies.
-
Experience in helping clients to reduce batch-batch variability and improve product quality and quantity.
Our track record of innovation
We have worked on a number of viral vector projects with multiple partners from SMEs to large corporates.
Innovation Insights
Read what our experts have to say on viral vectors.
Industry challenges
We know current methods of viral vector manufacture are highly inefficient which is putting a strain on drug developers and manufacturers alike.
- Upstream titer is low and inconsistent
- Poor scalability for adherent processes: 2D for process development to 3D for production
- Difficulties in process adaption from adherent to suspension
- Downstream recovery is low
- Analysis of yield and quality is hampered by limited analytical methods
- High cost of goods
Additionally, when we consider the manufacturing inefficiencies associated with viral vector manufacture such as spoilage, batch failures and QC sampling, organisations are needing to produce on average double the amount they need to accommodate the losses which is time consuming and costly.
Our viral vector capabilities
CPI can help you accelerate viral vector development towards in-human trials and enhance product manufacturability by improving process yield and reducing process variability by generating a robust, scalable and fully transferable process.
![<p>Accelerate process development.</p> <p>Accelerate process development.</p>](https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics_pipette.jpg?w=100&h=100&q=60&fm=jpg&fit=crop&dm=1578059980&s=abd66b7c5ac066697685c257a27b3590 100w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics_pipette.jpg?w=200&h=200&q=60&fm=jpg&fit=crop&dm=1578059980&s=f0a0fe6bd702de67abcb5c938b072417 200w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics_pipette.jpg?w=400&h=400&q=45&fm=jpg&fit=crop&dm=1578059980&s=bc86dbab32d6122fa873014676969983 400w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics_pipette.jpg?w=300&h=300&q=60&fm=jpg&fit=crop&dm=1578059980&s=5c9748c81bb814c9864934c4d4a4caf6 300w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics_pipette.jpg?w=600&h=600&q=45&fm=jpg&fit=crop&dm=1578059980&s=2f961aeea829c128f02571262f048972 600w)
Accelerate process development.
![<p>Improve process yield.</p> <p>Improve process yield.</p>](https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/lab-biopharmaceuticals.jpg?w=100&h=100&q=60&fm=jpg&fit=crop&dm=1560786982&s=bd6ba5d8afe109b7b55e9e4e899f9610 100w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/lab-biopharmaceuticals.jpg?w=200&h=200&q=60&fm=jpg&fit=crop&dm=1560786982&s=2b1841e87c5d8f39aa955f40ddb6bc5e 200w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/lab-biopharmaceuticals.jpg?w=400&h=400&q=45&fm=jpg&fit=crop&dm=1560786982&s=bc269dc0fe3ac4070ff829529c2b8280 400w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/lab-biopharmaceuticals.jpg?w=300&h=300&q=60&fm=jpg&fit=crop&dm=1560786982&s=f78ab172d8dd2b45a9fa2f0741615e46 300w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/lab-biopharmaceuticals.jpg?w=600&h=600&q=45&fm=jpg&fit=crop&dm=1560786982&s=023f3dad805c307354b14442626edf09 600w)
Improve process yield.
Reduce process variability.
![<p>Produce transferable processes.</p> <p>Produce transferable processes.</p>](https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-analytical-two-image.jpg?w=100&h=100&q=60&fm=jpg&fit=crop&dm=1559218265&s=8bc48c3876821f2cb97d6db20536d807 100w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-analytical-two-image.jpg?w=200&h=200&q=60&fm=jpg&fit=crop&dm=1559218265&s=2de3cf32d07a477dbd9b96c7ddd4f2bc 200w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-analytical-two-image.jpg?w=400&h=400&q=45&fm=jpg&fit=crop&dm=1559218265&s=a1ccb1d614963eed4698e8b3a42afaf1 400w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-analytical-two-image.jpg?w=300&h=300&q=60&fm=jpg&fit=crop&dm=1559218265&s=dd2fa118b2af3f451f63edd3c8a30aaf 300w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-analytical-two-image.jpg?w=600&h=600&q=45&fm=jpg&fit=crop&dm=1559218265&s=9ed459a5a2d0348cf6b3eabcefdc58bc 600w)
Produce transferable processes.
![<p>Improve process economics and scalability.</p> <p>Improve process economics and scalability.</p>](https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/national-biologics-02.jpg?w=100&h=100&q=60&fm=jpg&fit=crop&dm=1559211843&s=6d616cc8830938af1545924ec2f41a02 100w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/national-biologics-02.jpg?w=200&h=200&q=60&fm=jpg&fit=crop&dm=1559211843&s=cd04f0f4aece34d56a90020ac16ea04e 200w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/national-biologics-02.jpg?w=400&h=400&q=45&fm=jpg&fit=crop&dm=1559211843&s=9e245066b2cfad7061f8f19672d3e2ce 400w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/national-biologics-02.jpg?w=300&h=300&q=60&fm=jpg&fit=crop&dm=1559211843&s=692dd756ace60d90894535376533e156 300w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/national-biologics-02.jpg?w=600&h=600&q=45&fm=jpg&fit=crop&dm=1559211843&s=78277397d171b0d9057c202b444bcfc4 600w)
Improve process economics and scalability.
![<p>Consultancy.</p> <p>Consultancy.</p>](https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/contact-header.jpg?w=100&h=100&q=60&fm=jpg&fit=crop&dm=1579534173&s=725fe061da5c9899459ec99c13b6ee85 100w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/contact-header.jpg?w=200&h=200&q=60&fm=jpg&fit=crop&dm=1579534173&s=f101f956bac846452dfba79cce5fd155 200w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/contact-header.jpg?w=400&h=400&q=45&fm=jpg&fit=crop&dm=1579534173&s=96101f936b6efd05bfef5093f6c747e2 400w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/contact-header.jpg?w=300&h=300&q=60&fm=jpg&fit=crop&dm=1579534173&s=31acf7993319aeca2b444d34f75bd88e 300w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/contact-header.jpg?w=600&h=600&q=45&fm=jpg&fit=crop&dm=1579534173&s=23a17dff4a4e678f980f55c5ffffa967 600w)
Consultancy.
![Cell and Gene Therapy Catapult Cell and Gene Therapy Catapult](https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/CGTC_200218_113051.jpg?w=1920&h=1080&q=60&fm=jpg&fit=crop&dm=1582025451&s=2b68baa07113948a1ef97fc0d1287c58 1920w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/CGTC_200218_113051.jpg?w=1120&h=630&q=60&fm=jpg&fit=crop&dm=1582025451&s=f0ad30a067a4dc812ba0a84b56a08791 1120w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/CGTC_200218_113051.jpg?w=2240&h=1260&q=45&fm=jpg&fit=crop&dm=1582025451&s=74ce305ea03fcb73f03fe8fc0c220388 2240w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/CGTC_200218_113051.jpg?w=800&h=450&q=60&fm=jpg&fit=crop&dm=1582025451&s=15fe15eed1fe35505427d48f66a06532 800w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/CGTC_200218_113051.jpg?w=1600&h=900&q=45&fm=jpg&fit=crop&dm=1582025451&s=e12d972df93ec52c8e44b946a7183434 1600w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/CGTC_200218_113051.jpg?w=480&h=270&q=60&fm=jpg&fit=crop&dm=1582025451&s=ee4653954c3867da7d4311a1eb495f06 480w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/CGTC_200218_113051.jpg?w=960&h=540&q=45&fm=jpg&fit=crop&dm=1582025451&s=e53d9338564daab15c532e32e62867f3 960w)
A collaborative approach
CPI works closely with the Cell and Gene Therapy Catapult who bring a breadth of knowledge and experience in the area of viral vector processing. They offer:
- Access to 200+ cell and gene therapy experts
- MHRA-licensed GMP manufacturing facility
- Commercial readiness expert support
- Advanced Therapy Treatment Centre Network